The influence of domain permutations of an albumin-binding domain-fused her2-targeting affibody-based drug conjugate on tumor cell proliferation and therapy efficacy
Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the influence of the number and positioning of the protein domains in the drug conjugate. Seven HER2-targeti
